Atopic Dermatitis Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 10.06 Billion |
| Market Size (2029) | USD 14.23 Billion |
| CAGR (2024 - 2029) | 7.18 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Atopic Dermatitis Market Analysis
The Atopic Dermatitis Market size is estimated at USD 10.06 billion in 2024, and is expected to reach USD 14.23 billion by 2029, at a CAGR of 7.18% during the forecast period (2024-2029).
The significant factors fueling the market growth are the increasing burden of allergic reactions, an important role played by food allergy, and increasing environmental pollution. The growing burden of allergic reactions, with a significant role in food allergies, is driving the market growth. For instance, Food Allergy Research and Education (FARA) report in 2020 estimated that 32 million United States residents have food allergies, including 5.6 million children under age 18. About 40% of children with food allergies are allergic to more than one food.
Additionally, according to the Australian Society of Clinical Immunology and Allergy (ASCIA) update in May 2021, food allergy occurs in around 10% of infants, 4-8% of children, and about 2% of adults in Australia and New Zealand. Moreover, according to an article published in Nutrition Today Journal in February 2020, food allergy is a significant public health issue. It affects an estimated 3% to 10% of adults and 8% of children worldwide.
Likewise, accoring to a National Center for Biotechnology Information (NCBI) article in June 2020, infants with temporary skin barrier disruption and persistent atopic dermatitis are particularly at risk of developing food allergies. Among them, severe cases of atopic dermatitis with positive symptoms were observed in one-third of patients in an oral food challenge. As per the same study, many children with atopic dermatitis exhibit asymptomatic sensitization to foods. As food allergies result in atopic dermatitis, the increasing burden of allergic reactions across the globe is anticipated to increase the demand for treating atopic dermatitis worldwide, propelling the market growth.
Additionally, the regulatory authorities approvals are propelling the market's growth. For instance, in December 2021, LEO Pharma Inc. reported that the United States Food and Drug Administration (USFDA) approved Adbry (tralokinumab-Adam) for treating moderate-to-severe atopic dermatitis in adults 18 years or older.
The market is expected to show growth over the forecast period due to the abovementioned factors, such as the increasing burden of allergic reactions and product approvals. However, severe adverse effects of certain therapeutic drugs significantly hinder the market growth.
The COVID-19 pandemic significantly impacted the atopic dermatitis sector. As per an NCBI article published in March 2022, atopic dermatitis is associated with an increased risk of COVID-19 infection. Also, several initiatives were introduced to manage COVID-19 patients suffering from atopic dermatitis.
For instance, as per a June 2020 update, the SECURE-AD Patient survey is designed to help understand how the coronavirus pandemic (COVID-19) affects people with atopic dermatitis (also called atopic eczema). This survey encouraged the patient population with atopic dermatitis worldwide to participate and report their experience with COVID-19 infection. Such studies gathering the complications in patients with atopic dermatitis infected with COVID-19 provided the understanding and tolerability for various treatments of atopic dermatitis, thereby impacting the market growth. Thus, the pandemic significantly impacted the market's growth during the COVID peak stages. However, after the relaxation of strict regulations on patient consultations at healthcare centers, the current market scenario is expected to drive growth during the forecast period.
Atopic Dermatitis Market Trends
Corticosteroids Segment Dominated the Atopic Dermatitis Market Growth Over the Forecast Period
By drug class, the corticosteroid segment is anticipated to witness significant growth. Corticosteroids are referred to as cortisone-like medicines that are used as pain relief medications for inflammation in the body. These drugs reduce itching, swelling, allergic reactions, and redness. The major factors fueling the segment's growth are the increasing innovations leading to the advent of counterfeit medicines and alternative drugs and strategic initiatives undertaken by the market players.
According to the National Eczema Association (NEA) data published in 2022, corticosteroids are the most commonly prescribed medications for all eczema, reducing inflammation and itching. Corticosteroids have been used for over 60 years as topical medicines to treat many inflammatory skin conditions, including eczema. Such efficiency of the corticosteroids is expected to drive the growth of the studied segment over the forecast period.
Furthermore, Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in the third Phase 3 study. Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis.
The atopic dermatitis market size is anticipated to witness significant growth during the forecast period due to the increasing demand, the efficiency of corticosteroids, and increasing product developments.
North America is Expected to Witness a Significant Market Growth Over the Forecast Period
Within North America, the United States is expected to hold a significant market share. The major factors fueling the market growth are the increasing prevalence of atopic dermatitis, high treatment awareness among the patient population across the United States, well-established healthcare infrastructure, and early adoption of novel medications.
For instance, according to a Journal of the American Medical Association (JAMA) article published in June 2022, nearly 45% of survey participants reported having moderate atopic dermatitis, while 28% of the survey participants had severe atopic dermatitis in 2021. In addition, better reimbursement policies, increasing business partnerships of pharmaceutical companies with contract research organizations in emerging markets, and product developments are boosting the market's growth.
For instance, in February 2022, Evelo Biosciences, Inc., reported that the first patient had been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis. Also, in February 2021, the United States Food and Drug Administration (USFDA) accepted the Priority Review of New Drug Application (NDA) for Ruxolitinib Cream by Incyte Corporation, a selective JAK1/JAK2 inhibitor designed for topical application as a treatment for atopic dermatitis, a type of eczema.
Moreover, the increasing investments in atopic dermatitis are expected to contribute to this region's growth. For instance, according to a National Health Institutes (NIH) article published in June 2021, the estimated funding for atopic dermatitis research was USD 46 million in 2021 and USD 44 million in 2022.
Factors like increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and increasing operational activities help achieve significant atopic dermatitis market growth during the forecast period.
Atopic Dermatitis Industry Overview
The global atopic dermatitis sector is a moderately competitive market with major players dominating the market. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. The presence of major market players, such as Pfizer Inc., Novartis International AG, Allergan PLC, and Abbvie Inc., is increasing the overall competitive rivalry of the market studied.
Atopic Dermatitis Market Leaders
-
Pfizer Inc.
-
Abbvie Inc.
-
Bristol Myers Squibb
-
Regeneron Pharmaceuticals, Inc.
-
Evelo Biosciences, Inc.
*Disclaimer: Major Players sorted in no particular order
Atopic Dermatitis Market News
- October 2024: Regeneron Pharmaceuticals reported that its eczema treatment, Dupixent, contributed to better-than-expected third-quarter results, highlighting its strong demand.
- October 2024: Sanofi presented positive Phase 2b data for amlitelimab, a potential first-in-class treatment for moderate-to-severe atopic dermatitis. The results demonstrated significant improvements in disease signs and symptoms, supporting the initiation of a Phase 3 program in early 2024.
- September 2024: Eli Lilly received FDA approval for Ebglyss, an injectable drug for eczema, approved for use in adults and children over 12.
- April 2024: AbbVie's drug Rinvoq demonstrated superior efficacy compared to Regeneron's Dupixent in treating moderate-to-severe atopic dermatitis, according to a head-to-head study.
Atopic Dermatitis Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Allergic Reactions with Major Role of Food Allergy
4.2.2 Increasing Environmental Pollution
4.3 Market Restraints
4.3.1 Serious Adverse Effects Related to Certain Therapeutic Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Class
5.1.1 Corticosteroids
5.1.2 Emollients/Moisturizers
5.1.3 IL-4 and PDE4 Inhibitors
5.1.4 Calcineurin Inhibitors
5.1.5 Antibiotics
5.1.6 Other Drug Classes
5.2 By Route of Administration
5.2.1 Topical
5.2.2 Oral
5.2.3 Injectable
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Allergan PLC
6.1.3 Bausch Health Companies Inc.
6.1.4 GlaxoSmithKline PLC
6.1.5 Nestle SA
6.1.6 Pfizer Inc.
6.1.7 Regenron Pharmaceutical Inc.
6.1.8 Evelo Biosciences
6.1.9 Cara Therapeutics
6.1.10 Bristol-Myers Squibb Company
6.1.11 Sanofi S.A.
6.1.12 LEO Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Atopic Dermatitis Industry Segmentation
As per the scope of this report, atopic dermatitis, also known as atopic eczema, is often related as just a 'skin condition,' a misconception people think can be dealt with on their own. However, it impacts the patient's life physically and emotionally.
The atopic dermatitis sector is segmented by drug class (corticosteroids, emollients/moisturizers, il-4 and pde4 inhibitors, calcineurin inhibitors, antibiotics, and other drug classes), route of administration (topical, oral, and injectable), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).
The market report also covers the estimated market size and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Drug Class | |
| Corticosteroids | |
| Emollients/Moisturizers | |
| IL-4 and PDE4 Inhibitors | |
| Calcineurin Inhibitors | |
| Antibiotics | |
| Other Drug Classes |
| By Route of Administration | |
| Topical | |
| Oral | |
| Injectable |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Atopic Dermatitis Market Research FAQs
How big is the Atopic Dermatitis Market?
The Atopic Dermatitis Market size is expected to reach USD 10.06 billion in 2024 and grow at a CAGR of 7.18% to reach USD 14.23 billion by 2029.
What are the latest treatment trends in atopic dermatitis?
Latest atopic dermatitis treatments trends include IL-4 and PDE4 inhibitors like Dupilumab, combination therapies with corticosteroids, targeted immune therapies, and research into Janus kinase inhibitors and interleukins.
What are the main challenges facing the atopic dermatitis sector?
The atopic dermatitis sector faces challenges like high treatment costs, adverse drug effects, steroid phobia (notably in Japan), and diagnostic difficulties due to overlapping skin disorders.
What is the role of biologics in atopic dermatitis?
Biologics, especially IL-4 and PDE4 inhibitors like Dupilumab, are key in atopic dermatitis treatment, with new options in phase II trials targeting immune pathways.
What are the key demographic factors affecting the atopic dermatitis market?
Key demographic factors in this market include a higher prevalence in children (10-20%), a rising incidence in adults (around 5%), and greater occurrence in developed nations compared to developing ones.
What are the emerging therapies for atopic dermatitis?
The emerging therapies for atopic dermatitis include Biologics and Targeted Therapies, PDE4 Inhibitors, JAK Inhibitors, Interleukin Inhibitors, Small Molecule Drugs, Allergen-Specific Immunotherapy and Injectable Therapies.
Atopic Dermatitis Industry Report
The global atopic dermatitis drugs market analysis highlights a robust growth trajectory driven by increasing incidences of chronic diseases and heightened awareness of atopic dermatitis, characterized by dry, itchy, and inflamed skin. The market size is significantly influenced by the surge in biologics, which are expected to dominate due to their precision in targeting the condition, supported by new drug approvals and growing global acceptance. The injectable segment, particularly with drugs like dupilumab, stands out for its efficacy in managing symptoms, reinforcing the market's strength. Hospital pharmacies are emerging as primary distribution points, a trend supported by the widespread prevalence of atopic dermatitis and rising medication costs. North America holds a substantial market share, underpinned by strong healthcare systems and high levels of awareness. Meanwhile, the Asia Pacific region is positioned as a fast-growing market, driven by healthcare advancements, a growing patient base, and increased healthcare expenditure. Despite challenges such as high treatment costs and side effects associated with certain therapies, the market forecast projects continuous expansion. This growth is expected to bring innovative therapeutic breakthroughs and enhanced patient care. The industry analysis also indicates that market growth is supported by the industry's commitment to research and development, ensuring a steady stream of new and effective treatments. Overall, the market overview reveals a dynamic industry with a promising outlook, marked by significant market data and industry trends that point towards sustained growth. The market review further emphasizes the importance of market segmentation in understanding the diverse needs of patients and tailoring treatments accordingly. The industry reports and market predictions underscore the potential for continued advancements and improvements in patient outcomes, making the atopic dermatitis drugs market an area of keen interest for research companies and industry leaders alike.
Atopic Dermatitis Market Report Snapshots
